Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 14,055 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer directly owned 37,592 shares in the company, valued at $624,027.20. This trade represents a 27.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Houte Hans Van also recently made the following trade(s):
- On Thursday, April 30th, Houte Hans Van sold 2,388 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.65, for a total transaction of $39,760.20.
Nurix Therapeutics Price Performance
NASDAQ NRIX opened at $16.60 on Wednesday. The firm's fifty day moving average price is $15.85 and its 200 day moving average price is $16.13. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -5.25 and a beta of 1.87. Nurix Therapeutics, Inc. has a 12 month low of $8.19 and a 12 month high of $22.50.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.03). The company had revenue of $6.25 million during the quarter, compared to analysts' expectations of $14.25 million. Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. As a group, sell-side analysts forecast that Nurix Therapeutics, Inc. will post -2.94 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on NRIX. BTIG Research reissued a "buy" rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Needham & Company LLC reissued a "buy" rating and set a $26.00 price objective on shares of Nurix Therapeutics in a research report on Thursday, April 23rd. HC Wainwright reissued a "buy" rating and set a $32.00 price objective on shares of Nurix Therapeutics in a research report on Monday, April 27th. Piper Sandler raised their price objective on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the stock an "overweight" rating in a research report on Thursday, January 29th. Finally, Morgan Stanley set a $36.00 price objective on shares of Nurix Therapeutics and gave the stock an "overweight" rating in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $30.46.
Get Our Latest Research Report on Nurix Therapeutics
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Nurix Therapeutics by 11.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,804 shares of the company's stock valued at $593,000 after acquiring an additional 5,286 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Nurix Therapeutics by 106.2% in the first quarter. Millennium Management LLC now owns 874,399 shares of the company's stock valued at $10,388,000 after acquiring an additional 450,262 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Nurix Therapeutics by 9.5% in the first quarter. Goldman Sachs Group Inc. now owns 507,471 shares of the company's stock valued at $6,029,000 after acquiring an additional 44,002 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Nurix Therapeutics by 8.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 159,530 shares of the company's stock valued at $1,895,000 after acquiring an additional 12,817 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of Nurix Therapeutics in the second quarter valued at about $187,000.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.
The company's pipeline includes multiple programs in various stages of development.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
